Jason Liu, MD

Assistant Clinical Professor at @COH_RadOnc serving the lovely communities of South Pasadena & Glendale

[Kyle Colvett @KColvett]

Radiation oncology leadership need to simultaneously advocate for payment reform but emphasize that nothing else in the oncology world is as cost effective as radiation therapy.

Our economy spends more on a single drug—-pembrolizumab—-than all radiation treatments combined.

[Dan Golden MD MHPE @d_golden]

Thanks to @IJROBP & @sueyom for allowing me to share my #mentalhealth journey, "After #Burnout: Reigniting the Flame." I hope this essay can help others out there in medicine that might be struggling.

https://t.co/oQgvVaFkUd

#physicianburnout #anxiety #depression #wellness

[Jason Liu, MD @JasonRLiuMD]

Grateful for my work fam at @COH_RadOnc for throwing me and my wife the sweetest baby shower. Can’t ask for a better group of people to work with everyday. Expecting twin boys soon!

[City of Hope - Department of Radiation Oncology @COH_RadOnc]

Physician Spotlight:
@JasonRLiuMD is a COH trained rad onc at our South Pasadena network site. His office has recently implemented prone breast radiation and has treated >30 patients with osteoarthritis with LDRT. Clinical trials are also an option with a research nurse on staff!

[Jason Liu, MD @JasonRLiuMD]

@SeanPitroda @rweichselbaum @AndrasPiffko @IJROBP @NaturePortfolio @UChicago @UChicagoMed Thanks! Any explanation about how grid RT for bulky tumors can still have favorable local control and bystander effects without stimulating systemic tumor growth?

[Daniel E Spratt @DrSpratticus]

#astro25

@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.

Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased

3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.

Goodbye WPRT

[Jason Liu, MD @JasonRLiuMD]

@DrSpratticus @NRGonc Any subset analysis for just high risk pts? Don't think anyone does WPRT for intermediate risk pts. Thank you!

[PDBrown @PDBrownOnc]

Colleagues recent experience submitting RCT to top tier journal
This is ridiculous. Does it have to be so painful?
Like everything in life, too much or too little (peer review in this case) is not good!

[Giovanni Marchegiani @Gio_Marchegiani]

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @TheLancetOncol

Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR

⚖️ No difference in overall survival
😰 Serious adverse events 40%

👍 Both regimens may be considered

https://t.co/9nfnPUyhCR

[City of Hope @cityofhope]

We're proud to celebrate Robert Stone, CEO of @cityofhope, and @DrMvandenBrink, President of City of Hope Los Angeles and City of Hope National Medical Center, for being named to the @LABJnews 2025 LA500 list, honoring Los Angeles' most influential leaders. #LA500

[Youssef Zeidan MD, PhD @ZeidanMd]

🔥NSABP- B51 is out!
Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer

👉longer follow up desired
👉applicability across subtypes?
👉Impact of more modern systemic therapies ?
@NRGonc @ASTRO_org #BreastCancer
https://t.co/ISD7HOd5q7

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[NonsparseOncologist @5_utr]

❗️ Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer (ACHILES)

HR 1.14 (0.76-1.71)

👎 and makes me wonder re: ADRIATIC as well 🤔 #ASCO25

[Jason Liu, MD @JasonRLiuMD]

@COH_RadOnc @DocGlaser Well deserved! One of the best educators in all of rad onc

[City of Hope - Department of Radiation Oncology @COH_RadOnc]

We are excited to announce Dr. Scott Glaser in his new role as Residency Program Director. He is an excellent teacher, mentor, and incredibly committed to resident education. Congratulations on your new appointment.

[Jason Liu, MD @JasonRLiuMD]

@UCCancerCenter @Nature @rweichselbaum @AndrasPiffko @UChicagoRadonc Very interesting. Do you know how often this happens? Any idea if there are any patient/tumor specific variables that predict for amphiregulin expression?

[Sumanta K. Pal, MD, FASCO @montypal]

On this episode @DrEdKim & I dabble in discussions on his many contributions to #lungcancer, but go far beyond to discuss a holistic view of his approach to overseeing @cityofhope’s rapid expansion with research across #Chicago, #Atlanta & #Phoenix. I’ve known him as a tremendous leader during @cityofhopeoc’s inception - great to see the additional roles he is taking on at the institution.

Pinging my esteemed thoracic colleagues & others to have a listen & offer their feedback! Available on @ApplePodcasts & @Spotify - https://t.co/ugdzpPS8uU

@PatelOncology @StephenVLiu @HornLeora @VivekSubbiah @christine_lovly @DrJNaidoo @NarjustFlorezMD @DrRaviSalgia @LudaBazhenovaMD @peters_solange @DrRaviSalgia @ReckampK @DavidRSpigel @DrMarkAwad @AnaVManana @DrMvandenBrink @neerajaiims @PGrivasMDPhD @DrChoueiri @ASCO @AACR

[City of Hope @cityofhope]

Time’s running out! The deadline to vote in the @usnews #BestHospitals survey is March 23. Join @TeWilliamsMD and vote for @cityofhope!

Learn more: https://t.co/ttsSOoYmfU

[Jason Liu, MD @JasonRLiuMD]

@COH_RadOnc Congrats Eemon and @tomiwaawobayiku!